EGFR,c-Met和HER2/neu基因蛋白质在脊索瘤和其他肿瘤表达的特点

Expression of EGFR,c-Met and HER2/neu in chordoma and other cancers

目的:检测作为当前靶向治疗中的生物抑制剂EGFR,c-Met和HER2/neu3种抗体在12例脊索瘤中的表达。方法:对12例脊索瘤和包含17种其他肿瘤(共51个样本)的多肿瘤组织阵列切片进行免疫组化法的蛋白表达以及相关分析。结果:大多数脊索瘤显示EGFR和C-Met的过度表达,而c-Erb-B2的表达差异较大,并且EGFR和C-Met的表达存在显著的关联性(P=0.006)。结论:脊索瘤像其他实体瘤一样,也表达EGFR,c-Met和HER2/neu3种抗体,大部分脊索瘤对EGFR和C-Met的表达程度较高。EGFR抑制剂已在其他实体瘤进行临床试验,并为进行顽固性脊索瘤临床试验提供了理论依据。

Objective： To investigate the expression of c-Met, c-Erb-b2 and EGFR in 12 chordomas, based on the current and future availabihty of targeted molecular inhibitors. Method： Protein expression levels were analyzed by inmmnohistochemi analysis from 12 chordomas and 51 other tumors from 17 assorted solid tissue tumor types using multitumored tissue microarray. Results： Most chordomas displayed strong expression of EGFR and c-Met, while a variable level of expression of HER2/neu was observed. In addition, we noted a strong correlation between EGFR and c-Met expression, especially for primary chordomas （P = 0.006）. Conclusiol~： Chordoma, like many other solid-tissue tumors, expresses HER2/neu, EGFR and c-Met. Most chordoma has strong expression of both c-Met and EGFR. Inhibitors to EGFR are already in clinical use for other solid tissue tumors and represent a potentially viable experimental treatment option for refractory chordoma.